A pilot exercise involving 20,000 officials across 12 departments found that, while benefits were fairly consistent across ...

Natera (NasdaqGS:NTRA) recently presented compelling findings from a pan-cancer study of the Signatera Genome assay at the ASCO Annual Meeting, showcasing high sensitivity and specificity rates. The ...